| Rituximab therapy for membranous nephropathy: a systematic review. | |
| | |
MedLine Citation:
|
PMID: 19279120 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: The treatment of membranous nephropathy (MN) remains controversial. Rituximab, which selectively targets B cells, has emerged as a possible alternative treatment option with limited toxicity. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The available data on rituximab therapy for MN were reviewed using the MEDLINE database (inception to August 1, 2008), Google Scholar, and selected reference lists. English-language studies investigating the use of rituximab in idiopathic and secondary MN, in native and transplanted kidneys, were included. Study design, subject number, clinical characteristics (diagnosis, previous and concomitant treatment courses, baseline proteinuria, baseline renal function), rituximab protocol, follow-up period, achievement of complete or partial remission, changes in proteinuria and renal function, and adverse effects of therapy were extracted. RESULTS: Twenty-one articles were included for review; all were either case reports or case series without controls. More than half of the published cases (50 of 85) came from one center where rituximab was used as primary immunosuppression for idiopathic MN. The available data suggest that rituximab, dosed either as 375 mg/m(2) once weekly for 4 wk or as 1 g on days 1 and 15, achieves a 15 to 20% rate of complete remission and a 35 to 40% rate of partial remission. The drug was well tolerated with minimal adverse events. CONCLUSIONS: Although rituximab may prove to be a better treatment option for MN than alkylating agents or calcineurin inhibitors, the current literature only supports using the drug in research protocols. Whether, when, how, and why to use rituximab in MN remains to be determined. |
| | |
Authors:
|
Andrew S Bomback; Vimal K Derebail; Julie G McGregor; Abhijit V Kshirsagar; Ronald J Falk; Patrick H Nachman |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-03-11 |
Journal Detail:
|
Title: Clinical journal of the American Society of Nephrology : CJASN Volume: 4 ISSN: 1555-905X ISO Abbreviation: Clin J Am Soc Nephrol Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-06 Completed Date: 2009-06-08 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 101271570 Medline TA: Clin J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 734-44 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina Kidney Center, Chapel Hill, North Carolina 27599-7155, USA. abomback@unch.unc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / administration & dosage, adverse effects, therapeutic use* Antibodies, Monoclonal, Murine-Derived Drug Administration Schedule Glomerular Filtration Rate / drug effects Glomerulonephritis, Membranous / complications, drug therapy*, physiopathology Humans Immunosuppressive Agents / administration & dosage, adverse effects, therapeutic use* Kidney / drug effects*, physiopathology Middle Aged Proteinuria / etiology, prevention & control Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
T32 DK007750-09/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Murine-Derived; 0/Immunosuppressive Agents; 0/rituximab |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The U(L)31 and U(L)34 gene products of herpes simplex virus 1 are required for optimal localization ...
Next Document: Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases.